One‐year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo

Following a 21‐week double‐blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1‐year, open‐label study of treatment with AUR (6 mg/day). Results of this open‐label study suggest that AUR has a long‐term...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 1988-01, Vol.31 (1), p.9-14
Main Authors: James Williams, H., Dahl, Stephen L., Ward, John R., Karg, Miki, Willkens, Robert F., Meenan, Robert F., Altz‐Smith, Mary, Clegg, Daniel O., Mikkelsen, William M., Kay, Donald R., Weinstein, Arthur, Guttadauria, Maria, Paulus, Harold E., Kaplan, Stanley B.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - physiopathology
Auranofin - therapeutic use
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Clinical Trials as Topic
Follow-Up Studies
Gold Sodium Thiomalate - therapeutic use
Humans
Joints - physiopathology
Medical sciences
Pain
Patient Dropouts
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Following a 21‐week double‐blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1‐year, open‐label study of treatment with AUR (6 mg/day). Results of this open‐label study suggest that AUR has a long‐term use profile similar to that of other slow‐acting antirheumatic drugs. AUR appears to be capable of sustaining an initial response to gold sodium thiomalate. The withdrawal rate remains relatively high: Nearly half of the study patients had discontinued AUR by the end of 1 year.
ISSN:0004-3591
1529-0131
DOI:10.1002/art.1780310102